Clinical trials: Dupilumab
Localized Scleroderma
Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma
The DupiMorph study evaluates the efficacy of Dupilumab in localized scleroderma patients. Dupilumab is approved in the US and EU for the treatment of moderate/severe atopic dermatitis and since 2018 in the US for severe asthma…
- Trial name
- DupiMorph (NCT04200755)
- Testing
- Dupilumab 300Mg Solution for Injection
- Where
- 4 sites in Germany
- Volunteers
- 45 people
- Sponsor
- University of Cologne
Bullous Pemphigoid
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.
- Trial name
- NCT05906706
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Lung Cancer
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative…
- Trial name
- NCT05834413
- Testing
- chemotherapy plus TCM 1&ICIs plusTCM2
- Where
- China
- Volunteers
- 367 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Atopic Dermatitis
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.
- Trial name
- NCT04895423
- Testing
- Methotrexate therapy, Mycophenolate mofetil therapy, Cyclosporine therapy
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Moderate-to-severe Atopic Dermatitis
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Primary Objective: Part A To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score To determine the entry criterion…
- Trial name
- NEURADAD (NCT05203380)
- Testing
- dupilumab
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Evaluation of Dupilumab in Children With Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (<) 12 years of age with uncontrolled persistent asthma.
- Trial name
- VOYAGE (NCT02948959)
- Testing
- Dupilumab, Asthma Controller Therapies, Asthma Reliever Therapies
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 408 people
- Sponsor
- Sanofi
Healthy Volunteer
A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants
This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetics of 2 different dupilumab drug product in healthy volunteers. The duration per participant is up to 11 weeks.
- Trial name
- NCT05976360
- Testing
- Dupilumab (SAR231893)
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Sanofi
Eosinophilic Oesophagitis
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5…
- Trial name
- NCT06101095
- Testing
- Dupilumab
- Where
- 30 sites in United States, Brazil and 3 more
- Volunteers
- 69 people
- Sponsor
- Sanofi
Dermatitis, Atopic
A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies
The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as…
- Trial name
- NCT07887867
- Testing
- abrocitinib
- Volunteers
- 120 people
- Sponsor
- Pfizer
Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent
Dupilumab Therapy in Nephrotic Syndrome in Children
The goal of this clinical trial is to learn if dupilumab works to treat severe nephrotic syndrome in children. It will also learn about the safety of dupilumab.
- Trial name
- SMART-NS (NCT07091175)
- Testing
- Dupilumab, Co-intervention of Prednisolone wean during randomised controlled phase, Dupilumab open label extension phase
- Where
- 2 sites in Singapore
- Volunteers
- 66 people
- Sponsor
- National University Hospital, Singapore
Dermatitis, Atopic
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to <12 years of age with severe atopic dermatitis (AD).
- Trial name
- NCT03345914
- Testing
- Dupilumab, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 367 people
- Sponsor
- Regeneron Pharmaceuticals
Peanut Allergy
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients (6-17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the proportion of patients who…
- Trial name
- NCT03793608
- Testing
- Dupilumab
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
- Trial name
- NCT05602207
- Testing
- Abrocitinib
- Where
- 12 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Innovaderm Research Inc.
Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Switch-Up (NCT06389136)
- Testing
- Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
- Where
- 129 sites in United States, Canada and 7 more
- Volunteers
- 184 people
- Sponsor
- AbbVie
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer
Atopic Dermatitis
Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis
Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM)…
- Trial name
- DuHDM (NCT06509243)
- Testing
- tablets Acarizax, dupilumab, cyclosporine
- Where
- Poland
- Volunteers
- 132 people
- Sponsor
- Medical University of Silesia
Atopic Dermatitis
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01859988
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 380 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Disorder, Food Allergy
Gastrointestinal STRING Test With Oral Immunotherapy
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST).
- Trial name
- STRING (NCT04943744)
- Testing
- Entero-tracker, omalizumab, dupliumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis
Dupilumab in CRSsNP
Primary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: To evaluate the…
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder
- Trial name
- Liberty CRSsNP (NCT04678856)
- Testing
- Dupilumab SAR231893
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
Eosinophilic Esophagitis
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation.
- Trial name
- NCT05247866
- Testing
- Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Children's Hospital of Philadelphia